Palvella Therapeutics posts corporate presentation highlighting Phase 3 SELVA wins, NDA rolling review and $262M cash
I'm LongbridgeAI, I can summarize articles.Palvella Therapeutics released a corporate presentation highlighting positive Phase 3 SELVA results for QTORIN™ rapamycin, with FDA rolling review initiated and NDA completion targeted for H2 2026. The company anticipates U.S. launch in H1 2027, targeting over $1bn peak sales. Palvella holds $262M in cash and secured $230M in financing to support development across its pipeline of six rare disease programs.
Palvella Therapeutics posted a corporate presentation highlighting positive Phase 3 SELVA results, a rolling NDA submission for QTORIN™ rapamycin and plans for a potential 1H 2027 U.S. launch.
Key Highlights:
- Filed presentation (Exhibit 99.1) summarizes positive Phase 3 SELVA data: mean mLM-IGA +2.13 at Week 24 (p<0.001).
- Completed pre-NDA meeting; FDA granted rolling review and first NDA module submitted for microcystic LMs; NDA completion on track 2H 2026.
- Company expects potential FDA approval and U.S. launch for microcystic LMs in 1H 2027, targeting >30k diagnosed U.S. patients and >$1bn peak sales potential.
- Pipeline breadth: three QTORIN™ programs across six rare diseases anticipated by year-end 2026 with multiple near-term catalysts (Phase 3 start Q4 2026 for cutaneous VMs).
- Strong financial position: $262M cash as of 3/31/26 and $230M oversubscribed financing in Feb 2026 to support development and potential U.S. launch.
Original SEC Filing: PALVELLA THERAPEUTICS, INC. [ PVLA ] - 8-K - Jul. 14, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.